Biomarkers in the development of individualized treatment regimens for colorectal cancer
Abstract
Colorectal cancer (CRC) is the third most common and second most deadly malignancy in the world with an estimated 1. 9 million cases and 0.9 million deaths in 2020. The 5-year overall survival for stage I disease is 92% compared to a dismal 11% in stage IV disease. At initial presentation, up to 35% of patients have metastatic colorectal cancer (mCRC), and 20–50% of stage II and III patients eventually progress to mCRC. These statistics imply both that there is a proportion of early stage patients who are not receiving adequate treatment and that we are not adequately treating mCRC patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 30, 2022
- Source ID
- 10.3389/fmed.2022.1062423
Entities
People
- Madison Crutcher
- Scott A. Waldman
Organizations
- Congressionally Directed Medical Research Programs
- National Institutes of Health